162 related articles for article (PubMed ID: 37268749)
1. Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen.
Zhan Y; Ni K; Liu Z; Xin R; Han Q; Ping H; Liu Y; Zhao X; Wang W; Yan S; Sun J; Zhang Q; Wang G; Zhang Z; Zhang X; Hu X; Li G; Zhang C
Sci Rep; 2023 Jun; 13(1):8969. PubMed ID: 37268749
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
4. The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.
Liao L; Tang J; Hong Z; Jiang W; Li Y; Kong L; Han K; Hou Z; Zhang C; Zhou C; Zhang L; Sui Q; Xiao B; Mei W; Yu J; Yang W; Pan Z; Ding PR
BMC Cancer; 2024 Feb; 24(1):164. PubMed ID: 38302968
[TBL] [Abstract][Full Text] [Related]
5. Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods.
Zhang C; Zhan Y; Ni K; Liu Z; Xin R; Han Q; Li G; Ping H; Liu Y; Zhao X; Wang W; Yan S; Sun J; Zhang Q; Wang G; Zhang Z; Zhang X; Hu X
BMC Cancer; 2022 Nov; 22(1):1156. PubMed ID: 36352365
[TBL] [Abstract][Full Text] [Related]
6. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.
Tougeron D; Mouillet G; Trouilloud I; Lecomte T; Coriat R; Aparicio T; Des Guetz G; Lécaille C; Artru P; Sickersen G; Cauchin E; Sefrioui D; Boussaha T; Ferru A; Matysiak-Budnik T; Silvain C; Karayan-Tapon L; Pagès JC; Vernerey D; Bonnetain F; Michel P; Taïeb J; Zaanan A
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26839356
[TBL] [Abstract][Full Text] [Related]
8. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
[TBL] [Abstract][Full Text] [Related]
10. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
[TBL] [Abstract][Full Text] [Related]
11. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
[TBL] [Abstract][Full Text] [Related]
12. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P;
Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730
[No Abstract] [Full Text] [Related]
14. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
[TBL] [Abstract][Full Text] [Related]
15. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.
Sinicrope FA; Foster NR; Yoon HH; Smyrk TC; Kim GP; Allegra CJ; Yothers G; Nikcevich DA; Sargent DJ
J Clin Oncol; 2012 Feb; 30(4):406-12. PubMed ID: 22203756
[TBL] [Abstract][Full Text] [Related]
16. Choosing the Appropriate Individualized Adjuvant Chemotherapy in Stage III Colon Cancer Patients Under and Over 70 Years.
Taha HF; Harb OA; Gertallah LM; Abdelaziz LA
J Gastrointest Cancer; 2022 Sep; 53(3):581-591. PubMed ID: 34282542
[TBL] [Abstract][Full Text] [Related]
17. Should adjuvant chemotherapy be recommended to a 75-year-old woman with deficient mismatch repair (dMMR) gene product expression seen in a stage II colon adenocarcinoma with lymphovascular invasion?
Sorscher S
Curr Probl Cancer; 2018 Nov; 42(6):601-604. PubMed ID: 30119912
[TBL] [Abstract][Full Text] [Related]
18. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
20. Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer.
Shaib WL; Zakka KM; Jiang R; Yan M; Alese OB; Akce M; Wu C; Behera M; El-Rayes BF
Cancer; 2020 Sep; 126(18):4136-4147. PubMed ID: 32697360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
